Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(944/week)
    • Manufacturing(432/week)
    • Technology(950/week)
    • Energy(323/week)
    • Environment(352/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

CytRx Corporation

Aug 10, 2020
CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
Jul 21, 2020
CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
Jun 29, 2020
CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
Jun 01, 2020
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
May 26, 2020
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
May 21, 2020
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
Apr 29, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 11, 2020
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
Feb 04, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
Dec 19, 2019
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
Aug 09, 2019
CytRx Corporation Reports Second Quarter 2019 Financial Results
Jul 30, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
Jul 22, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
Jun 26, 2019
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
May 15, 2019
CytRx Corporation Reports First Quarter 2019 Financial Results
May 08, 2019
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
May 02, 2019
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
Apr 29, 2019
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
  •  
  • Page 1
  • ››

Latest News

Jun 2, 2025

Mitsubishi Electric Joins G7 Alliance on Nature Positive Economies

Jun 2, 2025

Faraday Future Holds First Annual Stockholders’ Day, Company Provides FX Product Updates, Confirms FX Super...

Jun 2, 2025

Défense: le Royaume-Uni détaille sa stratégie pour se réarmer face aux nouvelles menaces

Jun 2, 2025

UK to publish major defence review to face 'new era of threat'

Jun 1, 2025

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

Jun 1, 2025

Europe's Moonshot Moment: New Industry Report Suggests Now is Europe's Time to Lead in Global...

Jun 1, 2025

Zareef Hamid on the Rise of AI-Native Organizations

Jun 1, 2025

Statement from Canada Post - Canada Post responds to CUPW's request for binding arbitration

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia